



Developing breakthrough drugs urgently needed for an ageing global society

Investor Overview


November 2023

Cancer
Autoimmune diseases
Cardiovascular diseases
Neurodegenerative diseases

With these three beneficiaries in mind



patients




investors




national health budgets

.... our vision is to create drugs that finally offer meaningful progress in the treatment of diseases responsible for >50% of deaths worldwide and >80% of hospital admissions in a world that is increasingly ageing

Where we are start looking to make a difference ...



For the ~240 M people worldwide living with vision loss due to wet AMD and diabetic macular edema and who urgently require a better, safer treatment




For the estimated 300,000 men who die each year from prostate cancer and whose lives could be considerably improved through treatments considerably less disruptive to lifestyle



For the ~500,000 people diagnosed each year with pancreatic and bile duct cancers who urgently require an effective treatment

The problem we have sought to solve ...

The body's '*master switches*'



The complex circuitry that runs every cell involves a handful of *master switches* that oversee functions that are critical to the ability of every cell to perform normally.


But these *master switches* are not infallible. Almost all chronic diseases that result in death and disability involve malfunction of one or more of these *master switches*.

These *master switches* are validated drug targets, but the challenge has been how to turn off these switches when they are malfunctioning in diseased tissues without shutting down their vital roles in the rest of the body.

That challenge has proved largely insurmountable to date with these *master switches* essentially being 'off limits' when it comes to drug development because of unwanted toxicities.

This more than anything else is why medicine has made only modest progress in the treatment of chronic diseases such as many forms of cancer, heart disease, autoimmune diseases, Alzheimer's, Parkinson's etc.

Our solution ... currently 3 'breakthrough' technology platforms



Platform	Master switches involved
FLM-1	Vimentin, ERK, MAPK
FLM-2	Tribbles 2, ERK, MAPK
FLM-3	ERK, MAPK, JNK, Δ FosB

Three platforms providing a pipeline of drugs with *breakthrough* actions.

Drugs finally offering a way of dealing with malfunctioning *master switches* without causing catastrophic shutdowns in their essential functions throughout the rest of the body.

Drugs that Filamon is confident will finally offer the opportunity to correct *master switch* malfunctions in:

- most forms of cancer
- vision loss in seniors and diabetics
- atherosclerosis (heart disease, stroke)
- neuroinflammatory diseases (Alzheimer's, Parkinson's)
- and many of the 80+ autoimmune diseases.

Our strength is in our platforms

With many chronic diseases sharing the same error-prone '*master switches*', the very significant opportunity facing Filamon is the development of a family of drugs offering treatment across multiple major diseases

The cool thing about a platform is they're never one-trick ponies. If you have a single-molecule company and you invest in them and then they go into the clinic and fail ... then you fail. If you find a company that's an amazing platform with super smart people across a broad array of things, they're going to have more than one shot on goal. So, it's just a good investment.

Cathy Friedman
Executive Venture Partner
Google Ventures


April 2023

What makes Filamon different

Chronic diseases involve the misfiring of typically hundreds of different genes. Those genes range in importance to overall health from major to minor. Misfiring major genes (*'master switches'*) are far more important to the disease process but for safety reasons are considered 'undruggable' targets.

With safety paramount, pharmaceutical companies unsurprisingly have chased the low-hanging fruit of druggable (minor gene) targets. With misfiring *'master switches'* remaining uncorrected, the result is safer but less effective drugs.

Filamon is set to disrupt this paradigm by making previously undruggable 'master switches' druggable. Filamon is focused on the sweet spot between efficacy and safety that it believes will advance the treatment of many disease states.



Major needs

Lead drug program
(clinical stage)







Platform	Drug	Indications
Vimentin/sPLA ₂ -hGIIA inhibition	KS-c2	<p><i>Generally</i>: block the cancer-promoting effect of inflammation in cancer.</p> <p><i>Specifically</i>: delay need for chemical castration therapy in prostate cancer.</p>
Tribbles 2 inhibition	JG-1	<p><i>Generally</i>: reverse chemo-resistance in cancers.</p> <p><i>Specifically</i>: reverse resistance in prostate cancer cells to enzalutamide/abiraterone treatment.</p>
ERK/MAPK/JNK/ Δ FosB transcription	BT2-Topical	wet age-related macular degeneration.
	BT2-oral	block angiogenesis in cancer, reverse T-cell exhaustion

2x drugs in the clinic ...

1x drug being made clinic-ready ...

1x drugs in pre-clinical proof-of-concept phase ...

Molecule	Drug discovery	Pre-clinical	Phase Ia	Phase Ib	Phase Ib/IIa
KS-c2					
JG-1					
BT2-Topical					
BT2-Oral					

Taking advantage of key industry and demographic tailwinds



We have three
**breakthrough
drug** technology
platforms



Novel and without known competitors



Targeting the hot industry areas of need



Designed to complement existing treatments



Patient-friendly dosage forms & cost-effective treatments



Backed by commercially valuable IP


Path to commercialisation

Significant progress made already with **~\$30M spent in total on the 3 drug programs** to date

The commercial **focus is on major unmet needs in age-related illnesses** and hot spots of pharma industry M&A activity

The immediate goal is to **obtain proof-of-concept clinical data** as cost-effectively and as quickly as possible

Filamon will **undertake business development outreach to the pharma industry** in parallel with its clinical program as a key part of its business activities



Investment Value Drivers

Clinical-stage.
Early proof-of-
concept expected
starting 2024

5 initial drug
candidates each
targeting annual
market needs valued
at >US\$10 billion

A clear
commercialisation
pathway identified
to create investor
value

Uniquely acting
drugs with no known
direct competitors.
Backed by strong IP

US healthcare group,
Henry Ford Health, a
major partner

Experienced
leadership team with
the credentials to
execute

Experienced leadership team



Graham Kelly

BSc (Vet) (Hons), BVSc (Hons), PhD
Chairman and CEO

- 55 years' experience in medical research and drug development.
- Founder, Chairman and CEO of 4 listed public biotechnology companies - Noxopharm Ltd (ASX: NOX), Nyrada Inc (ASX: NYR), MEI Pharma Inc (NASDAQ: MEIP) and Novogen Ltd (now Kazia Therapeutics Ltd (NASDAQ: KZIA))
- Responsible for raising hundreds of millions of dollars in funding.



Dr Paul De Souza

BSc(Med), MBBS, MPH, PhD, FRACP
Non-Executive Director

- Experience starting at the University of Virginia to Eli Lilly Australia, then Medical Oncology Professor roles.
- Specialises in connecting drug development's preclinical and clinical facets.
- Focused on addressing the industry's "Valley of Death" challenge, transitioning molecules through clinics.



Philip A Marshall

BSc (Hons) PhD
Non-Executive Director

- Started from post-doctoral research at University College London to hands-on and executive management roles at Mayne Pharma, Pfizer, Numico and Aspen
- 40 years experience spanning drug discovery, formulation, manufacturing, pharmaceuticals, and regulatory compliance.
- Passion lies in optimising therapeutic efficiency, safety, and compliance in medicine development for a competitive edge.



Abhilasha Prasad

BA, MA, MGA
Non-Executive Director

- Abilasha (Lisa) Prasad is Vice-President and Chief Innovation Officer at Henry Ford Health System, Detroit, Michigan.
- Formerly co-founder and President of an investment firm focused on universities.
- Expertise in strategic utilisation of institutional IP assets.
- Holds a BA from University of Michigan, Master's from University of Pennsylvania in Government Administration and International Relations.







Kieran F. Scott

BSc (Hons) PhD
Chair, Scientific Advisory Board

- Currently, Associate Professor, Oncology: Currently at Western Sydney University, with extensive multidisciplinary research experience.
- Over 30 years' effort led to FLM-c2, a collaboration with numerous scientists and clinicians.
- Former President of Australian Society of Medical Research, NMHRC, and Ingham Foundation.

Company snapshot

An incubator company...	led by experienced executives...	dedicated to finding much-needed drug treatments...	based on unique 'breakthrough' technologies.
<p>Curating innovative new technologies from academic institutions, research centres, and biotech firms, repurposing abandoned drugs, and new ideas based on lateral thinking</p> 	<p>Experienced Board and executive in drug discovery, clinical trial execution, IP, start-up management, compliance</p> 	<p>Creating drugs to fill the large unmet needs across multiple major community illnesses</p> 	<p>Proprietary technology platforms breaking through the barrier that prevented the development of drugs against major drug targets</p> 

Important notice and disclaimer

This presentation, which includes all information and data on the following slides, any oral statements made when presenting these slides, and any other material distributed or statements made at, or in connection with, such presentation (the “Presentation”), relates to Filamon Ltd (the “Company”) is furnished to you solely for your information and may not be reproduced or redistributed, in whole or in part, to any other person without the prior written consent of the Company. By attending the meeting where this Presentation is made, or by reading the Presentation, you agree to be bound by the following limitations.

The Presentation may not be used for, or in connection with, any offer to, or solicitation by, any person in any jurisdiction or under any circumstances in which such offer or solicitation would not be authorized or lawful. The Presentation does not constitute or form part of, and should not be constructed as, any offer, invitation, solicitation or recommendation to purchase, sell or subscribe for any securities in the Company in any jurisdiction and does not constitute any form of commitment or recommendation on the part of the Company.

This Presentation is not a prospectus, and the Presentation may not be distributed other than in compliance with applicable securities laws and regulations. A prospectus relating to the Company or the contemplated investment has not been and will not be registered under any law or regulation, and any offering of securities in the Company will only be made pursuant to applicable exemptions in any relevant jurisdiction. The Presentation has not been approved or reviewed by any governmental authority or stock exchange in any jurisdiction. The Company has not decided whether to proceed with a transaction. The Presentation is intended to present background information on the Company, its business and the industry in which it operates and is not intended to provide complete disclosure. Prospective investors must solely rely on their own examination of the legal, financial, taxation and other consequences of an investment in the Company. Prospective investors should not treat the contents of the Presentation as an advice relating to legal, taxation or investment matters.

The Company makes no representation or warranty (whether express or implied) as to the correctness or completeness of the information contained herein, and neither the Company nor any of its affiliates, directors, employees or advisors assume any liability connected to the Presentation and/or the statements set out herein. The information included in this Presentation may contain certain forward-looking statements relating to the business, financial performance and results of the Company and/or the industry in which it operates. Forward-looking statements concern future circumstances and results and other statements that are not historical facts, sometimes identified by the words “believes”, “expects”, “predicts”, “intends”, “projects”, “plans”, “estimates”, “aims”, “foresees”, “anticipates”, “targets”, and similar expressions. The forward-looking statements contained in this Presentation, including assumptions, opinions and views of the Company or cited from third party sources are solely opinions and forecasts which are subject to risks, uncertainties and other factors that may cause actual events to differ materially from any anticipated development. Neither the Company nor any of its affiliates, directors, employees or advisors provides any assurance that the assumptions underlying such forward-looking statements are free from errors nor do any of them accept any responsibility for the future accuracy of the opinions expressed in this Presentation or the actual occurrence of the forecasted developments. This Presentation speaks as of the date hereof and there may have been changes in matters which affect the Company subsequent to the date of this Presentation.

Neither the issue nor delivery of this Presentation shall under any circumstance create any implication that the information contained herein is correct as of any time subsequent to the date hereof or that the affairs of the Company have not since changed, and the Company does not intend, and does not assume any obligation, to update or correct any information included in this Presentation.

The Presentation as well as any other information provided by or on behalf of the Company in connection herewith shall be governed by Australian law. The courts of Australia shall have exclusive jurisdiction to settle any conflict or dispute arising out of or in connection with the Presentation or related matters.



Investor Enquiries:

Dr Graham Kelly
info@filamon.com
www.filamon.com